In a clinical case study of a relapsed, metastatic ALK F1174L-mutated neuroblastoma patient, there was a complete response to lorlatinib initially that relapsed after 13 months, associating with development of an activating N-Ras Q61K mutation [111]. This evidence concerns the gene NRAS and neuroblastoma.